Please assess the completion status of the following clinical trial:

Trial Title: A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participants were male or female aged between 4 and 10 years (inclusive).~* Participants had a documented history of Dravet Syndrome that was not completely controlled by AEDs.~* Participants took one or more AEDs at a dose which had been stable for at least 4 weeks.~* Participants had experienced fewer than 4 convulsive seizures (tonic-clonic, tonic, clonic, atonic seizures) during the 28-day baseline period.~* All medications or interventions for epilepsy (including ketogenic diet and vagus nerve stimulation \[VNS\]) were stable for four weeks prior to screening and participants were willing to maintain a stable regimen throughout the study. The ketogenic diet and VNS treatments were not counted as an AED.~Key Exclusion Criteria:~* Participants had clinically significant unstable medical conditions other than epilepsy.~* Participants had clinically relevant abnormalities in the 12-lead electrocardiogram measured at screening or randomization.~* Participants were currently using or had in the past used recreational or medicinal cannabis, or synthetic CBD based medications (including Sativex®) within the 3 months prior to study entry and were unwilling to abstain for the duration for the study.~* Participants had any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMP.~* Participants who had been part of a clinical trial involving another investigational product in the previous 6 months.~* There were plans for the participants to travel outside their country of residence during the study.~* Participants were previously randomized into this study. In particular, participants participating in Part A of the study cannot enter Part B.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- GWP42003-P 5 mg/kg/day Dose (Type: EXPERIMENTAL): Participants received GWP42003-P 5 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 5 mg/kg/day over 3 days and remained at this dose for the rest of the 21-day treatment period (19 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
- GWP42003-P 10 mg/kg/day Dose (Type: EXPERIMENTAL): Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the rest of the 21-day treatment period (15 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
- GWP42003-P 20 mg/kg/day Dose (Type: EXPERIMENTAL): Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the rest of the 21-day treatment period (11 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo (0 mg/mL CBD), volume matched to one of the 3 dose levels (5, 10, or 20 mg/kg/day), administered orally, half in the morning and half in the evening for 21 days. To maintain the blinded aspect of the study, participants titrated the placebo dose over 3 to 11 days according to the matched investigational medicinal product (IMP) group (3, 7, and 11 days for the 5, 10, or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the rest of the 21-day treatment period. The 21-day treatment period was followed by a 10-day taper (10% per day of the matched dose) period.

Based on this trial design, predict the completion outcome and termination type (if applicable).